• (PLX AI) – Ambu shares are in for a tough day today after the company said last night it would not meet its guidance for the full year.
  • • Ambu now expects 2020/21 organic revenue growth of approx. 16%, down from 17% previously, and EBIT margin of 8.5-9.0% instead of 10%
  • • Total number of endoscopes sold was about 1.525 million units, where guidance was above 1.4 million units
  • • Ambu investors should brace themselves for another rollercoaster ride for the shares, Sydbank said
  • • Although Ambu exceeded its guidance on endoscope sales, the market already expected that number to be higher than 1.4 million, Sydbank said
  • • The EBIT margin cut is the main disappointment, SEB said
  • • EBIT consensus estimates should come down about 15% after this report, and there is risk of continued negative margin impacts on Ambu into the next year, SEB said
  • • While the endoscope sales are 4% above company consensus, indicative Visualisation revenue implies a 1% miss, Bank of America says
  • • This may mean analysts are expecting too much on the average selling price, which has been trending down due to an unfavorable mix, with more ENT/Urology scopes sold, which are lower priced, BofA said, reiterating an underperform recommendation on Ambu

Quelle: PLX AI